Neumora Therapeutics, Inc. (NMRA)
(Delayed Data from NSDQ)
$1.46 USD
-0.19 (-11.52%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $1.50 +0.04 (2.74%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth A Momentum D VGM
Fundamental Charts
About Market Cap
As of the previous market close, Neumora Therapeutics, Inc. has a market cap of $266.88M, which represents its share price of $1.65 multiplied by its outstanding shares number of 161.75M. As a small-cap company, NMRA's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
NMRA 1.46 -0.19(-11.52%)
Will NMRA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NMRA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NMRA
JNJ Halts Development of Depression Drug Over Efficacy Concerns
Biotech Stock Roundup: NMRA Plunges on Study Failure, HOTH, VIR Soar on Study Data & More
NMRA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Neumora Stock Hits Record Low on Depression Drug Study Failure
Other News for NMRA
Neumora outlines six upcoming clinical catalysts and prioritizes obesity program with NMRA-215
Neumora Therapeutics, Inc. (NMRA) Q2 2025 Earnings Call Transcript
Q2 2025 Neumora Therapeutics Inc Earnings Call Transcript
Neumora Therapeutics GAAP EPS of -$0.33
Neumora Therapeutics reports Q2 EPS (33c), consensus (37c)